PharmaCyte Biotech (PMCB) Equity Ratio (2016 - 2026)
PharmaCyte Biotech (PMCB) has disclosed Equity Ratio for 16 consecutive years, with 0.68 as the latest value for Q1 2026.
- Quarterly Equity Ratio fell 25.72% to 0.68 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.68 through Jan 2026, down 25.72% year-over-year, with the annual reading at 0.94 for FY2025, 103.8% up from the prior year.
- Equity Ratio for Q1 2026 was 0.68 at PharmaCyte Biotech, up from 0.63 in the prior quarter.
- The five-year high for Equity Ratio was 0.99 in Q1 2022, with the low at 0.44 in Q1 2024.
- Average Equity Ratio over 5 years is 0.79, with a median of 0.92 recorded in 2025.
- The sharpest move saw Equity Ratio plummeted 55.56% in 2024, then soared 108.87% in 2025.
- Over 5 years, Equity Ratio stood at 0.98 in 2022, then plummeted by 52.63% to 0.47 in 2023, then surged by 69.18% to 0.79 in 2024, then dropped by 20.18% to 0.63 in 2025, then increased by 8.37% to 0.68 in 2026.
- According to Business Quant data, Equity Ratio over the past three periods came in at 0.68, 0.63, and 0.97 for Q1 2026, Q4 2025, and Q3 2025 respectively.